Biocon

BIOCON.NS

Bengaluru, India· Est. 1978

biocon.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BIOCON.NS · Stock Price

INR 382.25+52.35 (+15.87%)

Market Cap: $6.5B

Historical price data

Overview

Biocon's mission is to deliver affordable, high-quality biopharmaceuticals to a global patient population. The company has achieved global leadership in biosimilars, with multiple commercialized products in oncology, immunology, and diabetes, and has built a fully integrated platform from R&D to manufacturing. Its strategy is anchored in leveraging its deep bioprocessing expertise to expand its biosimilar portfolio, advance a pipeline of novel biologics, and grow its contract research and manufacturing services.

OncologyImmunologyDiabetesAutoimmune Diseases

Technology Platform

Proprietary, integrated bioprocess engineering platforms for microbial and mammalian cell culture, enabling cost-effective, large-scale development and manufacturing of biosimilars and novel biologics.

Pipeline

23 drugs in pipeline7 in Phase 3

Drug	Indication	Stage
Stelara + Bmab1200	Moderate to Severe Chronic Plaque Psoriasis	Phase 3
EQ001 + EQ001 Placebo	Coronavirus	Phase 3
Itolizumab + EQ001 Placebo	Graft Versus Host Disease	Phase 3
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled...	Moderate Chronic Plaque Psoriasis	Phase 3
Bmab 1000 + Prolia®	Postmenopausal Women With Osteoporosis	Phase 3

Funding History

Total raised:$10M

IPO$10MUndisclosedMar 15, 2004

Series AUndisclosedUndisclosedJun 15, 1994

FDA Approved Drugs

SERTRALINE HYDROCHLORIDEANDAJan 20, 2026

EVEROLIMUSANDAJan 9, 2026

AUKELSOBLASep 16, 2025

Opportunities

The global biosimilars market is poised for exponential growth as blockbuster biologics lose patent protection, offering Biocon a vast expansion runway.

Additionally, the first interchangeable biosimilar insulin designation in the US unlocks a new, pharmacy-driven channel, and the growing global demand for biologics CDMO services provides a stable, high-margin revenue stream.

Risk Factors

Intense price competition in the biosimilars market, particularly in the US, threatens margin sustainability.

Regulatory delays or clinical setbacks for key pipeline assets could derail growth projections, and the complex integration of the acquired Viatris biosimilars portfolio carries significant execution risk.

Competitive Landscape

Biocon competes with large pharma biosimilar players (Pfizer, Sandoz) and agile biotechs (Celltrion) by leveraging its low-cost, integrated manufacturing and proven regulatory track record. In novel biologics, it faces competition from well-funded global biopharma, competing on innovation and speed-to-market.